Reviewer’s report

Title: Safety and survival effect comparison of adjuvant tamoxifen and toremifene in premenopausal patients with ER/PR positive breast cancer: a retrospective cohort study

Version: 12 Date: 23 October 2011

Reviewer: Rupert Bartsch

Reviewer’s report:

Safety and survival effect comparisons of adjuvant tamoxifen and toremifene in premenopausal patients with ER/PR positive breast cancer: a retrospective cohort study

Ran Gul et al.

Authors have revised their manuscript and addressed a number of criticisms. Some concerns, however, still remain.

1. Abstract, Introduction
   “We aimed to establish whether toremifene should be included in endocrine therapy for premenopausal patients with ER/PR positive breast cancer besides tamoxifen”
   As this is a retrospective analysis, I would rather state that authors tried to establish the potential role of toremifen in a retrospective study.

2. Abstract, Conclusion
   Again, this study is retrospective. Toremifene may (!) be an alternative to tamoxifen pending prospective validation...

2. Results
   Please provide HR and 95% CI for the results of the Cox regression model, perhaps in a separate table.

3. Discussion
   “We have shown that toremifene has the same survival effect as tamoxifen and has recurrence-free survival benefits for premenopausal patients”
   As outlined above, I would ameliorate such sentences as this is not a prospective study. Results of this retrospective analysis suggest similar efficacy of toremifene...

Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests